Drug major Sun Pharma will report its March quarter numbers (Q4FY23) tomorrow, May 26, as per the earnings calendar. The Dilip Shanghvi- founded company is expected to report a good set of numbers, as per the estimates of Zee Business Research.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

The company is expected to report a profit after tax (PAT) of Rs 1,982 crore for the January-March period against a loss of Rs 2,277 crore registered in the corresponding quarter of the preceding fiscal. It must be noted that the base year had an exceptional expense of Rs 3,936 crore.

Zee Business Research estimates the company's consolidated revenue to rise 16 per cent year-on-year (YoY) to Rs 10,980 crore against Rs 9,447 crore reported in the year-ago period. EBITDA or earnings before interest, tax, depreciation, and amortisation is pegged at Rs 2,844 crore, up 31 per cent against Rs 2,179 crore a year ago while margins are seen at 25.9 per cent vs 23.1 per cent.

ALSO READ: Sun Pharma Advanced Research Q4 net loss widens to Rs 81.99 crore

Further, Taro Pharma's encouraging results are also expected to support the company. Taro Pharma is a subsidiary of Sun Pharma. Besides, the speciality product portfolio is likely to witness growth and the US speciality business is estimated to grow by 18 per cent. Moreover, the Domestic formulation business is expected to see up to 9 per cent growth. These apart, potential launches over the next 12-15 months will be keenly watched.

STOCK PERFORMANCE

Shares of Sun Pharma have underperformed the benchmark indices in the last one-year period. The stock has risen over 4 per cent between May 25, 2022, and May 24, 2023, while the broader Nifty50 index has jumped 14 per cent during the window, Trendlyne data show.